Overview

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of multiple oral doses of LEO 32731 on the pharmacokinetics of a single oral dose of the cytochrome P450 3A substrate midazolam in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma
Treatments:
Midazolam